- Home
- VSAT vs NVCR Comparison
VSAT vs NVCR Comparison
Compare VSAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSAT
- NVCR
- Stock Information
- Founded
- VSAT 1986
- NVCR 2000
- Country
- VSAT United States
- NVCR Switzerland
- Employees
- VSAT N/A
- NVCR N/A
- Industry
- VSAT Radio And Television Broadcasting And Communications Equipment
- NVCR Medical/Dental Instruments
- Sector
- VSAT Technology
- NVCR Health Care
- Exchange
- VSAT Nasdaq
- NVCR Nasdaq
- Market Cap
- VSAT 1.2B
- NVCR 1.9B
- IPO Year
- VSAT 1996
- NVCR 2015
- Fundamental
- Price
- VSAT $16.28
- NVCR $17.71
- Analyst Decision
- VSAT Buy
- NVCR Buy
- Analyst Count
- VSAT 7
- NVCR 6
- Target Price
- VSAT $20.00
- NVCR $32.83
- AVG Volume (30 Days)
- VSAT 5.0M
- NVCR 1.6M
- Earning Date
- VSAT 08-06-2025
- NVCR 07-24-2025
- Dividend Yield
- VSAT N/A
- NVCR N/A
- EPS Growth
- VSAT N/A
- NVCR N/A
- EPS
- VSAT N/A
- NVCR N/A
- Revenue
- VSAT $4,519,571,000.00
- NVCR $621,711,000.00
- Revenue This Year
- VSAT $4.46
- NVCR $5.56
- Revenue Next Year
- VSAT $3.58
- NVCR $9.19
- P/E Ratio
- VSAT N/A
- NVCR N/A
- Revenue Growth
- VSAT 5.50
- NVCR 18.27
- 52 Week Low
- VSAT $6.69
- NVCR $14.17
- 52 Week High
- VSAT $26.70
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- VSAT 85.45
- NVCR 51.32
- Support Level
- VSAT $14.31
- NVCR $17.53
- Resistance Level
- VSAT $14.76
- NVCR $18.70
- Average True Range (ATR)
- VSAT 0.90
- NVCR 0.72
- MACD
- VSAT 0.26
- NVCR 0.09
- Stochastic Oscillator
- VSAT 95.09
- NVCR 60.56
About VSAT ViaSat Inc.
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.